APA (7th ed.) Citation

Napolitano, S., Martini, G., Ciardiello, D., Ciardiello, D., Maio, M. D., Normanno, N., . . . Ciardiello, F. (2022). CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Napolitano, Stefania, et al. CAVE-2 (Cetuximab-AVElumab) MCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type MCRC Patients. Frontiers Media S.A, 2022.

MLA (9th ed.) Citation

Napolitano, Stefania, et al. CAVE-2 (Cetuximab-AVElumab) MCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type MCRC Patients. Frontiers Media S.A, 2022.